Characterization and impact of response to holding/bridging therapy in second-line large Bcell lymphoma patients treated with axicabtagene ciloleucel: a LYSA study from the French DESCAR-T registry
Year: 2026
Type: article
Study design: Observational Study
Abstract: The optimal approach for holding or bridging therapy (H/BT) prior to second line axicabtagene ciloleucel (axi-cel) remains undefined, and the prognostic impact of response to H/BT remains debated. Here, we characterize real-world H/BT strategies and evaluate the impact of response on outcome following axi-cel infusion in the second-line setting for relapse or refractory (R/R) large B-cell lymphoma (LBCL). We included all adults with R/R LBCL within 12 months of first-line therapy who received axi-cel in the nationwide French DESCAR-T cohort (NCT04328298). The primary objective was to EFS between H/BT responders and nonresponders, as per Lugano criteria, using propensity score matching (PSM). Secondary objectives were to characterize H/BT modalities, corresponding responses, and to identify predictors of EFS at infusion. Among 566 patients included, 469 (83%) received chemotherapy-based H/BT, while 97 (17%) received a chemo-free approach, including no H/BT. Patients treated with chemotherapy-based H/BT had more advanced disease characteristics and exhibited inferior EFS compared to those receiving chemo-free approaches. After PSM, OS was significantly improved in responders versus non-responders (HR=0·70 [95% CI 0·51-0·96], p=0·0292), while the EFS benefit no longer reached statistical significance (HR=0·86 [95%CI 0·70-1·07], p=0·1739). Given that only patients ultimately receiving axi-cel were analyzed, the impact of H/BT response may have been underestimated. A predictive score combining response to H/BT, international prognostic index, LDH, and CRP at infusion identified two risk groups with significantly different EFS. In conclusion, H/BT response appears to be associated with axi-cel outcomes particularly when combined to inflammatory markers and residual LDH.
Source: Haematologica
Authors: Antoine Capes, Caroline Rossoni, Elodie Gat, Guillaume Cartron, François-Xavier Gros, Emmanuel Bachy, Guillaume Manson, Gabriel Brisou, Catherine Thieblemont, Stéphanie Guidez, Laurianne Drieu La Rochelle, Rémy Dulery, Florent Malard, Fabrice Jardin, Benoît Tessoulin, Fabien Le Bras, Franck Morschhauser, Amandine Durand, Cristina Castilla Llorente, Pierre Bories, Michaël Loschi, Sylvain Choquet, Gandhi-Laurent Damaj, Marie-Thérèse Rubio, Aline Tanguy-Schmidt, Jacques-Olivier Bay, Magalie Joris, Sylvain Carras, Laure Lebras, Julie Abraham, Jean-Valère Malfuson, Ludovic Fouillet, Olivier Hermine, Adrien Chauchet, Laura Herbreteau, Blandine Guffroy, Justine Decroocq, Steven Le Gouill, Roch Houot, Estelle Bourbon
Institutions: Hôpital Saint-Antoine, The Lymphoma Academic Research Organisation, Centre Hospitalier Universitaire de Montpellier, Centre Hospitalier Universitaire de Bordeaux, Hospices Civils de Lyon, Centre Hospitalier Universitaire de Rennes, Institut Paoli-Calmettes, Hôpital Saint-Louis, Centre Hospitalier Universitaire de Poitiers, Centre Hospitalier Universitaire de Tours, Centre Henri Becquerel, Centre Hospitalier Universitaire de Nantes, Hôpitaux Universitaires Henri-Mondor, Centre Hospitalier Universitaire de Lille, CHU Dijon Bourgogne, Institut Gustave Roussy, Centre Hospitalier Universitaire de Toulouse, Centre Hospitalier Universitaire de Nice, Pitié-Salpêtrière Hospital, Centre Hospitalier Universitaire de Caen Normandie, Centre Hospitalier Régional et Universitaire de Nancy, Centre Hospitalier Universitaire d'Angers, Centre Hospitalier Universitaire de Clermont-Ferrand, Centre Hospitalier Universitaire Amiens-Picardie, Centre Hospitalier Universitaire de Grenoble, Centre Léon Bérard, Centre Hospitalier Universitaire de Limoges, Hôpital Universitaire Dupuytren, Hôpital d'instruction des Armées Percy, Centre Hospitalier Universitaire de Saint-Étienne, Hôpital Necker-Enfants Malades, Centre Hospitalier Universitaire de Besançon, Centre Hospitalier Régional Universitaire de Brest, Hôpitaux Universitaires de Strasbourg, Hôpital Cochin, Institut Curie
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: axicabtagene ciloleucel, CAR T-cell therapy, large B-cell lymphoma, relapsed/refractory lymphoma, second-line therapy, bridging therapy, treatment response, event-free survival, overall survival, prognostic factors, International Prognostic Index, lactate dehydrogenase, C-reactive protein, inflammatory markers, risk stratification
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W7236828710
